Selecting the Right Nanomaterial for Your Drug Delivery Applications

• Small Molecules: Small molecule drugs are the most common form of therapeutics. They often suffer from poor solubility and short half-lives, which can limit their effectiveness. Nanoparticle-based delivery systems can address these limitations by enhancing solubility, prolonging circulation time, and controlling the release of the active ingredient, thus improving overall therapeutic efficacy.
• Peptides: Peptides, though increasingly used in targeted therapies, are highly susceptible to enzymatic degradation and poor bioavailability. As peptides are typically fragile in systemic circulation, nanoparticles can shield them from enzymatic breakdown, improve their stability, and enable precise delivery to the intended site of action.
• Proteins: Proteins, much like peptides, are complex and delicate molecules. Their use in therapeutics is limited by challenges such as instability and rapid degradation. Nanoparticles offer a protective environment for proteins, enhancing their stability, half-life, and ability to penetrate target cells for therapeutic action.
• Nucleic Acids: Nucleic acid-based drugs, including DNA and RNA therapies, hold tremendous potential for treating genetic disorders and cancers. However, their large size and susceptibility to degradation present significant delivery challenges. Nanoparticles help protect these molecules from degradation, enhance their delivery to target cells, and enable controlled release for sustained therapeutic effects.

Importance of Matching API Characteristics with Suitable Nanomaterials

A nanomedicine may be needed to deliver a therapeutic, to inhibit or promote enzymatic activity, to upregulate or down-regulate a particular pathway, induce apoptosis, or deliver genetic material. The nanomedicine needs to not only deliver the payload to the correct location but needs to maintain the appropriate concentration for sufficient time to be efficacious. Selecting the appropriate nanomaterial is therefore vital to optimizing the performance of an API. The nanoparticle carrier must align with the drug's size, charge, stability, and release characteristics to ensure effective delivery. For example, small, hydrophobic molecules can benefit from nanoparticles that improve solubility, while nucleic acids require highly stable carriers that protect them from degradation and facilitate their efficient cellular uptake. Ensuring compatibility between the API and the nanomaterial is crucial for maximizing drug delivery efficiency and achieving the desired therapeutic effect.

Lipid Nanoparticles

Lipid nanoparticles (LNPs) have gained popularity due to their biocompatibility and ease of formulation, especially for drug delivery of nucleic acids like mRNA. They form vesicular structures that can encapsulate both hydrophilic and hydrophobic compounds. While LNPs provide an efficient means for delivering genes and vaccines, they come with several limitations. One of the key challenges is their relatively low stability compared to other nanoparticles, which can lead to premature release or aggregation. Additionally, LNPs can be immunogenic, which might affect their long-term use for repeated therapies.

Silica Nanoparticles

Description and Properties of Solid and Mesoporous Silica Nanoparticles

Solid or porous silica (amorphous SiO2) nanoparticles can be reproducibly prepared across a range of sizes with high uniformity, and the surface can be readily modified using standard silane chemistry. Solid silica particles have nanopores that can incorporate low molecular weight species, or the surface may be functionalized to be highly positively charged to electrostatically adsorb genetic material, for example to deliver silencing RNA to specific cells.

Mesoporous silica nanoparticles (MSNs) are a promising subclass of silica particles, of interest in drug delivery systems due to their highly ordered internal porous structure and correspondingly large surface area. These features allow for high drug-loading capacity and precise control over drug release. MSNs can be functionalized with various chemical groups, enabling them to target specific tissues or cells, and to provide coatings that enable triggered release of the particle cargo. The mesoporous structure can be adjusted to optimize the loading and release rate of the encapsulated drug, making them highly versatile for both sustained and controlled drug delivery.

Benefits of MSNs for Drug Delivery

• High Biocompatibility and Biodegradability: MSNs are made from silica, a material that is well-tolerated by the human body. Silica’s biodegradability ensures that the nanoparticles break down into harmless components that can be safely eliminated from the body, making them suitable for long-term use in drug delivery.
• Versatile Surface Functionalization: One of the main advantages of MSNs is their ability to be tailored for specific targeting applications – using standard silane chemistry, it is possible to introduce a wide variety of surface functionalities, which can then enable further surface functionalization. The surface can be modified with biomolecules such as antibodies, peptides, or small molecules, which allow the nanoparticles to recognize and bind to specific cells or tissues, enabling highly targeted drug delivery, reducing side effects and increasing therapeutic efficacy.
• High Drug-Loading Capacity: The large surface area provided by the mesoporous structure of MSNs allows for efficient drug loading and; the capability of loading up to 30% by weight for small molecules in mesoporous silica has been demonstrated and it is not uncommon to reach 10% by weight for messenger RNA (mRNA) in large pore particles. The size of the pores may be tuned during synthesis to efficiently load API of different molecular weight.

Compatibility Across API Types

MSNs are highly versatile and can accommodate a wide range of API types, including small molecules, peptides, proteins, and nucleic acids. By adjusting the pore size and surface chemistry of MSNs, these nanoparticles can be fine-tuned to fit the specific characteristics of the drug being delivered, making them suitable for a broad spectrum of applications in drug delivery.

Considerations for Use

When using MSNs for drug delivery, it’s essential to consider factors such as the intended delivery route (oral, intravenous, etc.), the targeted tissue or organ, and the desired release profile (immediate vs. sustained). Additionally, the potential for silica accumulation and long-term biocompatibility should be evaluated in preclinical and clinical studies to ensure safety and efficacy.

Metal-Based Nanoparticles

Overview of Metal-Based Nanoparticles

Metal-based nanoparticles, such as gold and iron oxide, have unique optical, electronic, or magnetic properties that make them valuable components in drug delivery applications in combination with the associated API. The properties of the inorganic components can provide additional utility related to imaging, sensing, tracking, or may enable additional therapeutic modalities. Gold nanoparticles, for example, can be used for photothermal therapy, while iron oxide nanoparticles are used for magnetic resonance imaging (MRI) and magnetic drug targeting. The properties of the metal-based nanoparticle component may be adjusted by controlling the size, shape, and composition during synthesis.

Advantages and Uses of Metal-Based Nanoparticles

Gold Nanoparticles

Gold is the most widely used metal for nanoparticle drug delivery and therapeutic applications, due to the inert chemical properties of the material and general biocompatibility. Current interest in gold nanoparticles in nanomedicine typically exploit the unique optical properties of gold, specifically the localized surface plasmon resonance (LSPR) that can be tuned from visible to near infrared (NIR) wavelengths by changing the particle size and morphology. Gold nanoparticles are readily functionalized with a variety of ligands, which makes them adaptable for drug delivery, diagnostics, and imaging.

As a material with advanced capabilities in both the therapeutics and diagnostics realms, gold-based nanoparticles can be readily utilized as theranostics agents, combining these two application areas, and have been utilized in diverse applications ranging from two-photon luminescence to photodynamic and photothermal therapeutics, to identification of cells via Surface Enhanced Raman Spectroscopy (SERS).

Functionalized gold nanoparticles can release payloads in appropriate locations through irradiation by near-infrared (NIR) light leading to plasmonic heat generation. With the ability to be decorated with a variety of small molecule compounds, polymers, proteins, and nucleic acids, gold nanoparticles provide a versatile platform for delivering therapeutic cargos through the thermal stimulation of heat-responsive coatings.

Iron Oxide Nanoparticles

Iron oxide nanoparticles (IONPs), typically made of magnetite (Fe3O4) or maghemite (Fe2O3), have been widely studied and have been incorporated as components in FDA-approved medicines, such as those for treating iron deficiency. IONPs additionally exhibit size- and composition-dependent magnetic properties, which may be utilized in a number of different ways. The magnetic properties make them interesting candidates for MRI and related imaging applications, allowing the position within the body to be visualized and tracked. External fields may also be utilized to direct the particles to a specific site using an external magnetic field, enabling particles to be concentrated at tumor sites or directed across barriers within the body. Further, IONPs can also be used for local hyperthermia applications, similar to gold nanoparticles, but with the application of external alternating magnetic fields.

Suitable API Types for Metal-Based Nanoparticles

Metal nanoparticles are particularly effective for delivering proteins, peptides, and nucleic acids, which may be linked directly to the surface or attached through intermediate linker molecules. On gold nanoparticles, for example, thiol-based ligands attach strongly to the metal surface, providing a stable platform to introduce polymeric coatings or functional groups. In some cases, this thiol functionalization may be utilized directly, for example modifying oligonucleotides with a thiol group and directly binding to the gold surface. Alternatively, introduction of carboxylic acids using a heterobifunctional small molecule is often utilized for protein conjugation, enabling the use of standard EDC coupling between the acid group and amines within the protein to form covalent amide linkages.

Considerations for Use

When considering metal nanoparticles for drug delivery, factors such as particle size, surface charge, and the potential for toxicity must be carefully considered. Additionally, the long-term effects of the particles in the body and their ability to be cleared safely should be evaluated to ensure minimal adverse effects.

PLGA Nanoparticles

Introduction to PLGA Nanoparticles

Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are one of the most widely used biodegradable polymers in drug delivery and are generally regarded as safe, approved by both the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA) for use in vaccines, drug delivery, and tissue engineering. Recent research and development efforts have focused on changing this, from using PLGA not just as an inactive material but as an integral component of nanoparticle formulations that enable a wide range of nanomedicine applications including drug targeting and delivery, imaging, immunoassays, and medical devices.

PLGA is biocompatible and undergoes hydrolytic degradation, breaking down into lactic and glycolic acids, which are naturally metabolized by the body. These nanoparticles are highly versatile and can be used to encapsulate both hydrophobic and hydrophilic drugs, offering a broad range of applications in pharmaceutical formulations. Depending on the application needs, the synthesis route for the PLGA particles may be tuned to yield uniform particles in sizes between 100 nm to 1 µm. Successful development of PLGA nanoparticles as a delivery system requires precise loading and encapsulation of active ingredients, followed by their controlled release.

Benefits of PLGA Nanoparticles in Drug Delivery

• Biodegradability and Controlled Release: PLGA nanoparticles degrade gradually over time, releasing their drug payload at a controlled rate. This class of copolymer can be made with different ratios of lactic acid and glycolic acid to adjust material properties and the degradation rate in the body, along with selection of the total polymer molecular weight, provides additional tuning of degradation speed. This feature is particularly beneficial for drugs that require sustained release, improving the therapeutic effect and reducing the frequency of dosing.
• Targeted Delivery Capabilities: The terminal end groups of the polymer can also be chosen to create PLGA terminated with carboxylic acids, esters, and amines, providing a great deal of versatility in nanoparticle design and availability of specific chemical groups. Using these functional groups, PLGA nanoparticles can be further functionalized with targeting ligands to improve their specificity and increase the concentration of the drug at the site of action. This is particularly useful for targeting cancer cells or specific tissues to reduce side effects.

Compatibility with Various API Types

PLGA nanoparticles are highly versatile and can be used for delivering a wide range of APIs, including small molecules, proteins, peptides, and nucleic acids. Their ability to encapsulate hydrophobic drugs makes them especially useful in delivering poorly soluble molecules that might otherwise be challenging to formulate.

Considerations for Use

When designing PLGA nanoparticle-based drug delivery systems, it is important to consider the size, charge, and surface properties of the particles, as well as the encapsulation efficiency of the active ingredient. Factors such as the intended delivery route, target tissue, and desired therapeutic outcomes must also be carefully assessed to optimize the delivery system.

Conclusion

The selection of the right nanomaterial for drug delivery is a critical step in ensuring the success of therapeutic treatments. Nanoparticles provide unparalleled flexibility in terms of targeted delivery, controlled release, and improved drug stability. By carefully considering the characteristics of the drug and the properties of the nanomaterial, pharmaceutical companies can develop drug delivery systems that enhance patient outcomes, minimize side effects, and provide long-lasting therapeutic effects.

Reach out to our team to learn how we can bring your nanomedicine innovation to life: